Ann F. Hanham Ph.D.

Ann F. Hanham Ph.D.

Chairman at HTG Molecular Diagnostics, Inc.

Are you Ann F. Hanham Ph.D.? Claim your profile
 
  • IDENTIFY executive and board member connections in Ann F. Hanham Ph.D.'s network.
  • FOLLOW changes in Ann F. Hanham Ph.D.'s employment.
  • CONNECT with Ann F. Hanham Ph.D. through your network of contacts.

Ann F. Hanham Ph.D.'s Executive Work History


Current
Chairman,
Chairman
HTG Molecular Diagnostics, Inc. DEF 14A on 07/07/2022
HTG Molecular Diagnostics, Inc.
Board Member,
Board Member
SCYNEXIS, Inc. DEF 14A on 05/12/2022
SCYNEXIS, Inc.
Past
To view Ann F. Hanham Ph.D.'s complete executive work history,
Education
Ph.D., University of British Columbia
Simon Fraser University
University of Toronto
Age
69
 

Ann F. Hanham Ph.D.'s Biography


Dr. Hanham has served on our Board of Directors since August 2016 and has served as chair of our Board of Directors since January 2021. Prior to this, Dr. Hanham served as Lead Independent Director from April 2019 to December 2020 and as chair of our Board of Directors from March 2017 to March 2019. Since March 2017, Dr. Hanham has provided independent management consulting as a sole proprietor. Previously, she was the founding and managing partner of BAR Capital LLC, an investment company, a position she has held from December 2013 to March 2017. From February 2000 to November 2013, Dr. Hanham was the Managing Director and General Partner of Burrill and Company, a life science investment company. Prior to that, Dr. Hanham held positions of increasing responsibility in product development, medical affairs, and clinical and regulatory affairs at various companies, including InterMune Inc., Otsuka America Pharmaceuticals, Inc. ("Otsuka"), Celtrix Pharmaceuticals, Inc. ("Celtrix"), and Becton Dickinson and Company ("BD"). InterMune, Inc., Otsuka and Celtrix are, or prior to respective acquisitions, were clinical-stage biopharmaceutical companies, and BD is a life sciences discovery and diagnostics company. Dr. Hanham also currently serves on the board of directors of SCYNEXIS (Nasdaq: SCYX). Dr. Hanham received her Bachelor of Science degree from the University of Toronto, Canada; her M.Sc. degree, in biology, from Simon Fraser University, Canada; and her Ph.D. degree, in biology, from the University of British Columbia, Canada. Our Board of Directors believes that Dr. Hanham's extensive industry and executive experience, and her experience serving on the board of directors of other public companies qualifies her to serve on our Board of Directors.

Source: HTG Molecular Diagnostics, Inc. on 07/07/2022

 

By accessing ExecAtlas, you can view bios, network, connections and references of industry leading executives like Ann F. Hanham Ph.D.. More specifically, you'll be able to:

  • IDENTIFY executive and board member connections in Ann F. Hanham Ph.D.'s network.
  • FOLLOW changes in Ann F. Hanham Ph.D.'s employment.
  • CONNECT with Ann F. Hanham Ph.D. through your network of contacts.
 

Access over 1,500,000 executive and board member profiles.

Example: Ann F. Hanham Ph.D.

Ann F. Hanham Ph.D.'s Connections (95)


Merouane Bencherif
Former Vice President, Preclinical Research, Catalyst Biosciences, Inc.
Philip S. Low Ph.D.
Chief Scientific Officer, On Target Laboratories
Allen R. Ritter
Head of CMC, ConSynance Therapeutics
Dr. Richard A. Messmann
Chief Medical Officer, Apexian Pharmaceuticals, Inc.
Harry A. George
Founder President and Chief Financial Officer, Radiance Therapeutics, Inc.
Marc D. Kozin
Board Member, UFP Technologies, Inc.
James Samuel Shannon M.D.
Board Member, ProQR Therapeutics N.V.
Edward E. Penhoet Ph.D.
Director, Alta Partners
Christopher B. Ehrlich
CEO and Secretary, Phoenix Biotech Acquisition Corp.
Seth A. Rudnick M.D.
Venture Partner, Pitango Venture Capital